Cameron, D, Morden, J P, Canney, P, Velikova, G, Coleman, R, Bartlett, J, Agrawal, R, Banerji, J, Bertelli, G, Bloomfield, D, Brunt, A M, Earl, H, Ellis, P, Gaunt, C, Gillman, A, Hearfield, N, Laing, R, Murray, N, Couper, N, Stein, R C, Verrill, M, Wardley, A & Barrett-Lee, P & Bliss, J M 2017, ' Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial ', The Lancet Oncology, vol. 18, no. 7, pp. 929-945 . https://doi.org/10.1016/S1470-2045(17)30404-7 The Lancet. Oncology